secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-01-03T23:59:59+00:00
Accession:  0000950170-25-001140
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health receives Nasdaq delisting notice; hearing requested, reverse split proposed
--------------------------------------------------------------------------------

- Nasdaq notified Tivic on Dec 27, 2024 it failed to regain $1.00 bid price compliance and is ineligible for a second 180-day period due to equity deficiency.
- Company requested a hearing on Jan 3, 2025, which automatically stays any suspension or delisting pending the hearing and Panel decision.
- Special stockholder meeting set for Jan 31, 2025 to vote on reverse stock split (ratio 1:2 to 1:30) to regain bid price compliance.
- No assurance that the company will regain compliance or that the Nasdaq Panel will grant continued listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/0000950170-25-001140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/tivc-20241227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-001140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer